Sara B. Strauss

Sara B. Strauss

Auto-generated profile, based on publicly available information

Sara B. Strauss

From Zwanger-Pesiri Radiology Associates, 150 E Sunrise Hwy, Lindenhurst, NY 11757 (D.R.S.); and Department of Radiology, NewYork-Presbyterian/Weill Cornell Medical Center, New York, NY (S.B.S.).

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2020 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
JLJ.E. Lantos
J.E. Lantos
SSS.B. Strauss
S.B. Strauss
ELE. Lin
E. Lin
SUMMARY: Miller Fisher syndrome, also known as Miller Fisher variant of Guillain-Barré syndrome, is an acute peripheral neuropathy that can develop after exposure to various viral, bacterial, and fungal pathogens. It is characterized by a triad of ophthalmoplegia, ataxia, and areflexia. Miller Fisher syndrome has recently been described in the clinical setting of the novel coronavirus disease 2019 (COVID-19) without accompanying imaging. In this case, we report the first presumptive case of COVID-19–associated Miller Fisher syndrome with MR imaging findings.

20 August 2020 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
ELE. Lin
E. Lin
JLJ.E. Lantos
J.E. Lantos
SSS.B. Strauss
S.B. Strauss
CPC. Douglas Phillips
C. Douglas Phillips
TCT.R. Campion
T.R. Campion
AGA. Gupta
A. Gupta
BACKGROUND AND PURPOSE: A large spectrum of neurologic disease has been reported in patients with coronavirus disease 2019 (COVID-19) infection. Our aim was to investigate the yield of neuroimaging in patients with COVID-19 undergoing CT or MR imaging of the brain and to describe associated imaging findings. MATERIALS AND METHODS: We performed a retrospective cohort study involving 2054 patients with laboratory-confirmed COVID-19 presenting to 2 hospitals in New York City between March 4 and May 9, 2020, of whom 278 (14%) underwent either CT or MR imaging of the brain. All images initially received a formal interpretation from a neuroradiologist within the institution and were subsequently reviewed by 2 neuroradiologists in consensus, with disputes resolved by a third neuroradiologist. RESULTS: The median age of these patients was 64 years (interquartile range, 50–75 years), and 43% were women. Among imaged patients, 58 (21%) demonstrated acute or subacute neuroimaging findings, the most common including cerebral infarctions (11%), parenchymal hematomas (3.6%), and posterior reversible encephalopathy syndrome (1.1%). Among the 51 patients with MR imaging examinations, 26 (51%) demonstrated acute or subacute findings; notable findings included 6 cases of cranial nerve abnormalities (including 4 patients with olfactory bulb abnormalities) and 3 patients with a microhemorrhage pattern compatible with critical illness–associated microbleeds. CONCLUSIONS: Our experience confirms the wide range of neurologic imaging findings in patients with COVID-19 and suggests the need for further studies to optimize management for these patients.

27 August 2020 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
SSS.B. Strauss
S.B. Strauss
JLJ.E. Lantos
J.E. Lantos
LHL.A. Heier
L.A. Heier
DSD.R. Shatzkes
D.R. Shatzkes
CPC. Douglas Phillips
C. Douglas Phillips
BACKGROUND AND PURPOSE: Unique among the acute neurologic manifestations of Severe Acute Respiratory Syndrome coronavirus 2, the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic, is chemosensory dysfunction (anosmia or dysgeusia), which can be seen in patients who are otherwise oligosymptomatic or even asymptomatic. The purpose of this study was to determine if there is imaging evidence of olfactory apparatus pathology in patients with COVID-19 and neurologic symptoms. MATERIALS AND METHODS: A retrospective case-control study compared the olfactory bulb and olfactory tract signal intensity on thin-section T2WI and postcontrast 3D T2 FLAIR images in patients with COVID-19 and neurologic symptoms, and age-matched controls imaged for olfactory dysfunction. RESULTS: There was a significant difference in normalized olfactory bulb T2 FLAIR signal intensity between the patients with COVID-19 and the controls with anosmia (P = .003). Four of 12 patients with COVID-19 demonstrated intraneural T2 signal hyperintensity on postcontrast 3D T2 FLAIR compared with none of the 12 patients among the controls with anosmia (P = .028). CONCLUSIONS: Olfactory bulb 3D T2 FLAIR signal intensity was greater in the patients with COVID-19 and neurologic symptoms compared with an age-matched control group with olfactory dysfunction, and this was qualitatively apparent in 4 of 12 patients with COVID-19. Analysis of these preliminary finding suggests that olfactory apparatus vulnerability to COVID-19 might be supported on conventional neuroimaging and may serve as a noninvasive biomarker of infection.

30 April 2020 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
JCJ.L. Chazen
J.L. Chazen
MRM.S. Robbins
M.S. Robbins
SSS.B. Strauss
S.B. Strauss
ASA.D. Schweitzer
A.D. Schweitzer
JGJeffrey P Greenfield
Jeffrey P Greenfield
SUMMARY: CSF-venous fistula is an important treatable cause of spontaneous intracranial hypotension that is often difficult to detect using traditional imaging techniques. Herein, we describe the technical aspects and diagnostic performance of MR myelography when used for identifying CSF-venous fistulas. We report 3 cases in which the CSF-venous fistula was occult on CT myelography but readily detected using MR myelography.

1 April 2021 in Brain Imaging and Behavior
Verified
Journal Article
Closed access
PDF file
SSSara B. Strauss
Sara B. Strauss
RFRoman Fleysher
Roman Fleysher
CIChloe Ifrah
Chloe Ifrah
LHLiane E. Hunter
Liane E. Hunter
KYKenny Ye
Kenny Ye
MLMichael L. Lipton
Michael L. Lipton

9 June 2016 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
SSS.B. Strauss
S.B. Strauss
NKNamhee Kim
Namhee Kim
CBC.A. Branch
C.A. Branch
MKM.E. Kahn
M.E. Kahn
MKM. Kim
M. Kim
MLM.L. Lipton
M.L. Lipton
BACKGROUND AND PURPOSE: Mild traumatic brain injury results in a heterogeneous constellation of deficits and symptoms that persist in a subset of patients. This prospective longitudinal study identifies early diffusion tensor imaging biomarkers of mild traumatic brain injury that significantly relate to outcomes at 1 year following injury. MATERIALS AND METHODS: DTI was performed on 39 subjects with mild traumatic brain injury within 16 days of injury and 40 controls; 26 subjects with mild traumatic brain injury returned for follow-up at 1 year. We identified subject-specific regions of abnormally high and low fractional anisotropy and calculated mean fractional anisotropy, axial diffusivity, radial diffusivity, and mean diffusivity across all white matter voxels brain-wide and each of several white matter regions. Assessment of cognitive performance and symptom burden was performed at 1 year. RESULTS: Significant associations of brain-wide DTI measures and outcomes included the following: mean radial diffusivity and mean diffusivity with memory; and mean fractional anisotropy, radial diffusivity, and mean diffusivity with health-related quality of life. Significant differences in outcomes were found between subjects with and without abnormally high fractional anisotropy for the following white matter regions and outcome measures: left frontal lobe and left temporal lobe with attention at 1 year, left and right cerebelli with somatic postconcussion symptoms at 1 year, and right thalamus with emotional postconcussion symptoms at 1 year. CONCLUSIONS: Individualized assessment of DTI abnormalities significantly relates to long-term outcomes in mild traumatic brain injury. Abnormally high fractional anisotropy is significantly associated with better outcomes and might represent an imaging correlate of postinjury compensatory processes.